Merck & Co. reported mixed Q3 2026 results with sales growth but a significant decline in net income and EPS. The company also highlighted new drug approvals and strategic acquisitions, indicating ongoing portfolio expansion and future growth drivers.
Merck & Co. announced its Q3 2026 financial results, showing a 4.7% increase in total sales to $18.09 billion, but a 12.4% decline in net income and EPS. This mixed performance, coupled with the disclosure of a $550 million U.S. sales boost due to purchase timing that is expected to reverse, presents a nuanced picture for investors. The company also highlighted significant positive developments, including new U.S. drug approvals for Lipfendra and Idvynso, multiple indication expansions for Keytruda and Keytruda Qlex, and strategic acquisitions of Terns, Cidara, and TARGAN, along with a licensing deal for a KRAS G12D candidate. These new approvals and acquisitions are crucial for Merck's long-term growth strategy, particularly in oncology and influenza prevention, and could offset the short-term financial headwinds. Traders will be weighing the immediate impact of the earnings decline against the long-term potential of the expanded pipeline and portfolio.